ANI Pharmaceuticals, Inc. (ANIP)

Over the past six months, ANI Pharmaceuticals' stock price has been influenced by several events. The company reported record fourth-quarter and full-year 2025 financial results and reaffirmed its 2026 financial guidance, which was followed by a share decline and subsequent drift higher. The FDA approval and launch of Isosorbide Mononitrate Tablet and the publication of NEW DAY Clinical Trial Results in Ophthalmology also impacted the stock. Analyst ratings from Guggenheim, Barclays, Wall Street Zen, and Zacks Research have influenced the stock, as well as insider selling. The company's 52-week high was $99.50, and its 52-week low was $56.71.

Demand for ANI Pharmaceuticals' products can exhibit some seasonality and fluctuations. Strong demand for Purified Cortrophin Gel was observed despite typical Q1 insurance resets. Demand for ILUVIEN and YUTIQ was impacted by Medicare-related issues in the first quarter of 2025, with anticipation of a return to more normalized demand levels during the second quarter. The generics business has shown strong performance, driven by new product launches and operational execution.

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing branded and generic prescription pharmaceutical products, including those for diseases with high unmet medical needs. The company operates through Rare Disease and Brands, and Generics and Other segments. Its major products include Purified Cortrophin Gel, ILUVIEN, and YUTIQ, with product development areas encompassing narcotics, oncolytics, hormones, steroids, and complex formulations. ANI Pharmaceuticals has a commercial portfolio of approximately 118 products.

ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota, with a commercial headquarters in Princeton, New Jersey. The company operates three pharmaceutical manufacturing facilities in the U.S., two in Baudette, Minnesota, and one in East Windsor, New Jersey, capable of producing various forms of products. The majority of the company's revenue is derived from the U.S. market.

ANI Pharmaceuticals' brand reputation has been positively influenced by strong financial results, driven by its Rare Disease and Generics business units. The lead rare disease asset, Purified Cortrophin Gel, has shown exceptional growth. The acquisition of Alimera Sciences positioned its Rare Disease segment as a primary growth engine. The FDA approval and launch of Isosorbide Mononitrate Tablet and the publication of positive clinical trial results for ILUVIEN in ophthalmology also contribute to a favorable reputation.

ANI Pharmaceuticals, Inc. has significant institutional ownership, with 283 institutional owners and shareholders holding a total of 21,039,910 shares, accounting for 92.04% of the company. Individuals hold 8.44%. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, State Street Corp, Global Alpha Capital Management Ltd., Millennium Management Llc, Dimensional Fund Advisors Lp, Soleus Capital Management, L.P., Tang Capital Management Llc, Deep Track Capital, LP, and Geode Capital Management, Llc.